NASDAQ$ETNB
89Bio Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
89bio's financial results for Q1 2024 were reported, along with a corporate update.
89bio reported a net loss of $51.7 million for the first quarter of 2024. The company initiated the Phase 3 ENLIGHTEN-Fibrosis trial and expects to initiate the ENLIGHTEN-Cirrhosis trial this quarter. They also received PRIME status from the EMA for pegozafermin in MASH treatment.
- Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH patients.
- Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH patients with compensated cirrhosis.
- Granted PRIME status from EMA for pegozafermin in treating MASH with fibrosis and compensated cirrhosis.
- Data from the 48-Week Extension Phase of the ENLIVEN Phase 2b Trial to be presented at EASL.
Headline financials
Revenue & EPS history
89Bio · Revenue · Quarterly
$0
Forward guidance
89bio anticipates topline data from the ENTRUST Phase 3 trial in SHTG in 2025 and is focused on executing Phase 3 trials for MASH.
Tailwinds
- On track to begin the ENLIGHTEN-Cirrhosis trial for compensated cirrhotic MASH patients in the second quarter.
- Pegozafermin has the potential to be the leading therapy in treating advanced MASH patients with fibrosis.
- Focused on the execution of Phase 3 trials for MASH and the synergistic Phase 3 trial in severe hypertriglyceridemia (SHTG).
- Agreement for commercial supply is designed to strategically enhance readiness for potential commercialization.
- Enrollment continues to progress well in ENTRUST, the Phase 3 trial evaluating the efficacy, safety, and tolerability of pegozafermin in patients with SHTG.
Headwinds
- Trial outcomes are subject to various risks and uncertainties.
- Positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies.
- Substantial dependence on the success of lead product candidate.
- Competition from competing products.
- Impact of general economic, health, industrial or political conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q1 2024
-0.1%
Avg return
Earnings day
-4.6%
Avg return
5 days after
-2.8%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+14.8%
Q4 2019
Best reaction
-19.4%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +1.7% | +1.3% | -1.7% | |
| Q1 2025 | -3.7% | -4.1% | +18.6% | |
| Q4 2024 | -1.0% | -7.1% | -3.7% | |
| Q3 2024 | +2.8% | -10.9% | -20.6% | |
| Q2 2024 | -10.9% | -11.8% | -0.9% | |
| Q1 2024 | -3.5% | +0.8% | -10.2% | |
| Q4 2023 | +7.3% | -0.2% | -1.3% | |
| Q3 2023 | -11.8% | — | — | |
| Q2 2023 | +5.3% | — | — | |
| Q1 2023 | +1.3% | — | — | |
| Q4 2022 | -1.1% | — | — | |
| Q3 2022 | +14.2% | — | — | |
| Q2 2022 | +3.6% | — | — | |
| Q1 2022 | +14.6% | — | — | |
| Q4 2021 | +5.1% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | +1.1% | — | — | |
| Q1 2021 | -19.4% | — | — | |
| Q4 2020 | -4.7% | — | — | |
| Q3 2020 | -0.8% | — | — | |
| Q2 2020 | +1.6% | — | — | |
| Q1 2020 | -6.2% | — | — | |
| Q4 2019 | +14.8% | — | — | |
| Q3 2019 | -13.5% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro